Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals, Inc. (PHAT): 9 pipeline candidates · 5 upcoming catalysts · ~40 mo cash runway · 7 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
40.2 months
D/E -1.91 · 3% dilution
Lead: Approved
9 candidates
5 upcoming, next in ~561d
N/A
A transparent, data-derived signal for Phathom Pharmaceuticals, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$877.3M
Cash
$180.9M
Quarterly Burn
$15.6M
Runway
40.2 mo
Revenue
$58.3M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (9 candidates)
| Drug | Phase |
|---|---|
| Vonoprazan | Phase 3 |
| vonoprazan (VOQUEZNA) | Phase 3 |
| vonoprazan (VOQUEZNA) - as-needed regimen | Phase 3 |
| vonoprazan (VOQUEZNA) - EoE | Phase 3 |
| Vonoprazan ODT-1 or ODT-2 with Water | Phase 1 |
| Vonoprazan ODT-1 or ODT-2 without Water | Phase 1 |
| VOQUEZNA | Approved |
| VOQUEZNA DUAL PAK | Approved |
| VOQUEZNA TRIPLE PAK | Approved |
Upcoming Catalysts (5)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
170
Total value held
$455.1M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 5,167,272 | $57.4M |
| blackrock, inc. | 4,061,996 | $45.1M |
| millennium management llc | 4,022,909 | $44.7M |
| 683 capital management, llc | 1,850,000 | $20.6M |
| perceptive advisors llc | 1,850,000 | $20.6M |
| catalys pacific, llc | 1,493,854 | $16.6M |
| state street corp | 1,386,890 | $15.4M |
| wasatch advisors lp | 1,340,916 | $14.9M |
| geode capital management, llc | 1,328,045 | $14.8M |
| nomura asset management international inc. | 1,205,369 | $13.4M |
Showing top 10 of 170 institutional holders of Phathom Pharmaceuticals, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Phathom Pharmaceuticals, Inc.'s pipeline?
Phathom Pharmaceuticals, Inc. (PHAT) has 9 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Phathom Pharmaceuticals, Inc.'s lead drug candidate?
Phathom Pharmaceuticals, Inc.'s most advanced tracked candidate is Vonoprazan (Phase 3) for Erosive Esophagitis; Gastroesophageal Reflux; Eosinophilic Esophagitis.
What is Phathom Pharmaceuticals, Inc.'s next catalyst?
Phathom Pharmaceuticals, Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: voquezna" — expected December 31, 2027.
What is Phathom Pharmaceuticals, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Phathom Pharmaceuticals, Inc. has approximately 40.2 months of cash runway.
What is Phathom Pharmaceuticals, Inc.'s market capitalization?
Phathom Pharmaceuticals, Inc.'s market capitalization is approximately $877.3M.
Get the full picture on Phathom Pharmaceuticals, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.